Sulforaphane impaired immune checkpoint blockade therapy through activating ΔNP63α/PD-L1 axis in gastric cancer.
Mol Carcinog
; 63(8): 1611-1620, 2024 Aug.
Article
en En
| MEDLINE
| ID: mdl-38780147
ABSTRACT
Sulforaphane (SFN) exerts anticancer effect on various cancers including gastric cancer. However, the regulatory effect of SFN on programmed death-ligand 1 (PD-L1) and checkpoint blockade therapy in gastric cancer have not been elucidated. Here we demonstrated that SFN suppressed gastric cancer cell growth both in vitro and in vivo study. SFN upregulated PD-L1 expression through activating ΔNP63α in gastric cancer cells. Further, we found that SFN impaired the anticancer effect of anti-PD-L1 monoclonal antibody (α-PD-L1 mab) on gastric cancer cells. These results uncover a novel PD-L1 regulatory mechanism and the double-edged role of SFN in gastric cancer intervention.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias Gástricas
/
Sulfóxidos
/
Factores de Transcripción
/
Isotiocianatos
/
Antígeno B7-H1
/
Inhibidores de Puntos de Control Inmunológico
Límite:
Animals
/
Humans
Idioma:
En
Año:
2024
Tipo del documento:
Article